Used in the treatment of autoimmune diseases where uncontrolled complement system activation causes tissue damage. Specifically targets and inhibits complement component C2, blocking the classical and lectin pathways of the complement cascade. This inhibition helps prevent inflammation and cell lysis in conditions such as autoimmune hemolytic anemia, lupus nephritis, and other complement-mediated disorders. Investigated in preclinical and clinical studies for its potential to reduce disease activity with a favorable safety profile due to selective pathway inhibition.